Prostate Cancer
Medication Prescription Policy for US Veterans With Metastatic Castration-Resistant Prostate Cancer: Causal Machine Learning Approach.
December 23, 2024
Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.
December 23, 2024
Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).
December 23, 2024
Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer.
December 23, 2024
Performance of PSMA-PET/CT as verified by bone biopsy for diagnosing osseous metastases of prostate cancer.
December 23, 2024
Landscape and prognostic significance of oncogene drivers in metastatic castration sensitive prostate cancer.
December 20, 2024
Optimal Treatment Strategies for Hormone-sensitive Metastatic Prostate Cancer: Does Local Radiotherapy Play a Role in High-volume Disease?
December 20, 2024
HRS Improves Active Surveillance for Prostate Cancer by Timely Identification of Progression.
December 20, 2024
PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity.
December 20, 2024
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men.
December 20, 2024
Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis.
December 19, 2024